Cadrenal Therapeutics Inc. is a biopharmaceutical company. It focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug designation for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. Cadrenal Therapeutics Inc. is based in PONTE VEDRA, Fla.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-10.65M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 4.24 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -244.94% |
| Return on Assets (Trailing 12 Months) | -181.94% |
| Current Ratio (Most Recent Fiscal Quarter) | 4.32 |
| Quick Ratio (Most Recent Fiscal Quarter) | 4.32 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $3.11 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-2.09 |
| Earnings per Share (Most Recent Fiscal Year) | $-8.73 |
| Diluted Earnings per Share (Trailing 12 Months) | $-9.26 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 1.97M |
| Free Float | 1.01M |
| Market Capitalization | $26.28M |
| Average Volume (Last 20 Days) | 0.02M |
| Beta (Past 60 Months) | 1.46 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 48.62% |
| Percentage Held By Institutions (Latest 13F Reports) | 7.92% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |